Marengo Therapeutics
CompanyUnited States
Marengo Therapeutics develops one asset, in phase 2 (Invikafusp alfa in tumor mutational burden-high solid tumors). Mostly protein or enzyme; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 2
- Trials
- 0
- Signals
Pipeline
1Activates selected T cells through T-cell receptor binding and interleukin-2 signaling.
Phase 2, Protein or enzyme, tumor mutational burden-high solid tumors, bladder cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials2
- Similar companies6